# Alkermes plc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Alkermes plc.). ## Overview Alkermes plc is a biopharmaceutical company focused on neuroscience, with commercial medicines for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. Its business combines proprietary branded products with manufacturing and royalty revenue from partnered products developed under license. The company is headquartered in Ireland, with a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio. In 2026 it expanded its commercial portfolio by acquiring Avadel Pharmaceuticals and adding LUMRYZ, a narcolepsy treatment, to its marketed products. ## Products & services • ARISTADA and ARISTADA INITIO for schizophrenia • LYBALVI for schizophrenia and bipolar I disorder • VIVITROL for alcohol and opioid dependence • LUMRYZ for narcolepsy symptoms • Manufacturing revenue for partnered products • Royalty revenue from licensed neuroscience products - **Proprietary commercial products** (70%) — Branded medicines that Alkermes markets and sells itself, including treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence and narcolepsy. - **Manufacturing revenue** (20%) — Revenue from producing products for licensees and other partners, including legacy and partnered medicines manufactured at Alkermes facilities or through contractors. - **Royalty revenue** (10%) — Royalties earned on sales of licensed products that incorporate Alkermes technology, where partners commercialize the medicine and pay usage-based royalties. - ARISTADA and ARISTADA INITIO for schizophrenia - LYBALVI for schizophrenia and bipolar I disorder - VIVITROL for alcohol and opioid dependence - LUMRYZ for narcolepsy symptoms - Manufacturing revenue for partnered products - Royalty revenue from licensed neuroscience products ## Customers Alkermes sells primarily into the U.S. pharmaceutical channel, where wholesalers, specialty distributors and pharmacies purchase its proprietary products. The end users are physicians and treatment systems serving patients with serious psychiatric and substance-use disorders, so demand is driven by prescribing behavior, reimbursement access and treatment adherence. For partnered products, the direct customers are licensees and sublicensees that commercialize products using Alkermes technology and pay manufacturing or royalty fees. The company also serves public treatment systems and private practice physicians through its sales and education efforts, reflecting a mix of commercial and healthcare-system buyers. - **U.S. pharmaceutical distribution channel** (primary) — Wholesalers, specialty distributors and pharmacies purchase proprietary products for resale and dispensing, making this the core commercial route for ARISTADA, LYBALVI, VIVITROL and LUMRYZ. - **Physicians and treatment systems** (primary) — Psychiatrists, addiction-treatment providers and public health systems prescribe or administer Alkermes medicines because they address chronic neuropsychiatric and substance-use conditions. - **Licensees and partners** (secondary) — Biopharma partners that commercialize products incorporating Alkermes technology buy manufacturing capacity or generate royalty streams for the company. - **Payers and managed care intermediaries** (secondary) — Insurers, Medicaid and Medicare Part D programs influence uptake through rebates, formulary access and reimbursement terms, especially for VIVITROL and other branded therapies. - Wholesalers and specialty distributors buying branded medicines for resale - Pharmacies dispensing ARISTADA, LYBALVI, VIVITROL and LUMRYZ - Physicians in private practice prescribing to individual patients - Public treatment systems treating addiction and serious mental illness - Licensees and sublicensees that buy manufacturing services or pay royalties - Patients are the end users, but access depends on prescribers and payers ## Geography Alkermes is headquartered in Ireland but operates a U.S.-centric commercial model, with its marketed products sold primarily in the United States. The company also has a corporate office and R&D center in Massachusetts and a manufacturing facility in Wilmington, Ohio, which anchors production of several proprietary products and microspheres for partnered medicines. Some manufacturing and royalty revenue is earned outside the U.S., and the company notes exposure to foreign-currency movements on those revenues and related expenses. Operationally, the geography mix matters because U.S. commercial execution drives most revenue, while Ireland is relevant for tax and corporate structure and Ohio is critical for supply continuity. - United States is the main commercial market for proprietary products - Massachusetts hosts corporate and R&D activities - Wilmington, Ohio is the key manufacturing site for several products - Ireland is the corporate headquarters and tax domicile - Some manufacturing and royalty revenue comes from outside the U.S. - Foreign-currency exposure matters for non-U.S. revenue and costs ## Strategy Alkermes is focused on growing a neuroscience portfolio built around differentiated commercial products and selective business development. Near term, the company is emphasizing execution on ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL and newly acquired LUMRYZ, while continuing to support manufacturing and royalty streams from partnered products. It also seeks to expand through transactions, licenses and collaborations that add products, candidates or technologies with commercial fit. This strategy matters because the company depends on a relatively concentrated set of branded medicines, so adding durable assets and protecting supply/manufacturing reliability are central to sustaining growth. - **Commercial execution for proprietary products** (short-term) — Most revenue comes from a concentrated set of branded medicines, so uptake, access and retention are critical to growth. - **Portfolio expansion through M&A and licensing** (medium-term) — The company wants to reduce concentration risk and add assets that fit its neuroscience commercial infrastructure. - **Manufacturing and supply reliability** (short-term) — Product shortages or quality issues could directly reduce sales and damage reputation in regulated pharmaceutical markets. - Drive U.S. commercialization of proprietary neuroscience products - Integrate LUMRYZ into the portfolio after the Avadel acquisition - Protect and expand manufacturing and royalty revenue from partners - Pursue acquisitions, licenses and collaborations to broaden the pipeline - Maintain reliable supply from the Ohio manufacturing base - Invest in differentiated products that can compete in crowded CNS markets ## Risks Alkermes is exposed to concentration risk because a large share of revenue comes from a small number of proprietary products, so any loss of exclusivity, slower uptake or reimbursement pressure could materially affect results. Manufacturing risk is also significant because the company relies on complex pharmaceutical production, third-party contractors and regulated supply chains; quality deviations, shortages or site disruptions could delay shipments or trigger recalls. Competition is intense in neuroscience and addiction treatment, including from branded and generic rivals as well as products from licensees that may compete with Alkermes medicines. The company also faces foreign-currency exposure on non-U.S. manufacturing and royalty revenue, plus legal and IP risk around products such as INVEGA TRINZA and other licensed assets. - **Concentration in key proprietary products** [high] — The company says substantial revenue comes from its key proprietary products, so any decline in demand or access can have an outsized effect on earnings. - **Manufacturing and supply-chain disruption** [high] — Pharmaceutical manufacturing is complex and disruptions in API, quality, equipment, labor or logistics can cause shortages, recalls or lost sales. - **Competition in neuroscience and addiction markets** [medium] — Competing branded therapies, generics and alternative treatments can pressure pricing, market share and physician adoption. - **Controlled-substance regulatory burden** [medium] — LUMRYZ and sodium oxybate are subject to DEA quotas and heightened controls, which can constrain manufacturing and distribution. - **Foreign-currency exposure** [low] — Some manufacturing and royalty revenues are earned outside the U.S. and denominated in local currencies, creating translation and transaction risk. - Revenue concentration in a small number of proprietary products - Manufacturing interruptions, quality failures or supply shortages - DEA and controlled-substance regulation for LUMRYZ and sodium oxybate - Competition from branded, generic and partner-controlled products - Patent and IP litigation risk on licensed or competing products - Foreign-currency volatility on non-U.S. manufacturing and royalty revenue ## Accounting Alkermes recognizes product sales when customers obtain control of the goods, while manufacturing revenue is generally recognized at a point in time when control passes to the licensee. Some manufacturing arrangements use end-market sales prices supplied by licensees, so the company must estimate revenue and later true-up differences, which can create quarter-to-quarter variability. Royalty revenue is recognized when the licensee sells the product because the royalties are sales-based and payable in the period of sale. Investors should also watch Medicaid rebates, Medicare Part D accruals and other contractual adjustments, since these estimates can materially affect net product sales and are sensitive to utilization and payer mix. - **Revenue recognition under ASC 606** — Can shift reported revenue between quarters depending on shipment timing and licensee sales - **Manufacturing revenue estimation and true-ups** — Creates short-term volatility and potential adjustments within the same quarter - **Medicaid rebates and Medicare Part D accruals** — Can materially affect reported net sales and margins - **Controlled-substance inventory and supply chain accounting** — May affect cost of goods sold and inventory valuation - Point-in-time revenue recognition for product sales and manufacturing revenue - Estimated manufacturing pricing based on licensee end-market sales data - Sales-based royalty recognition when licensee sales occur - Medicaid rebate and Medicare Part D accrual estimates - Quarterly true-ups for manufacturing revenue estimates - Potential volatility from product mix and payer utilization --- *Last updated: 2026-08-11T04:46:19.984528+00:00*